All In Biotech

Drug Trial Radar · NCT00975897

Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer

FOCUS 3 - A Study to Determine the Feasibility of Molecular Selection of Therapy Using KRAS, BRAF and Topo-1 in Patients With Metastatic or Locally Advanced Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Dec 19, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 3,240 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,240

Planned (sponsor's estimate)

Start

Jul 2009

Primary completion

Aug 2010

Study completion Dec 2012

Sponsor

Lead sponsor
Medical Research CouncilGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Sep 14, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors select the best treatment for patients and predict their response to treatment. PURPOSE: This randomized phase II/III trial is studying how well tumor tissue testing works in selecting treatment for patients with metastatic or locally advanced colorectal cancer.

Conditions

  • Colorectal Cancer

Interventions

  • bevacizumabBiological

  • cetuximabBiological

  • fluorouracilDrug

  • irinotecan hydrochlorideDrug

  • leucovorin calciumDrug

  • oxaliplatinDrug

  • RNA analysisGenetic

  • cytogenetic analysisGenetic

  • fluorescence in situ hybridizationGenetic

  • gene expression analysisGenetic

  • mutation analysisGenetic

  • protein expression analysisGenetic

  • diagnostic laboratory biomarker analysisOther

  • immunohistochemistry staining methodOther

  • questionnaire administrationOther

  • cognitive assessmentProcedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Topoisomerase-1 (topo-1) and K-ras, BRAF results obtained within 10 working days after registration
  2. Number of patients in which the interval between registration and randomization (RZ) is ≤ 10 days
  3. Efficacy of fluorouracil with vs without irinotecan hydrochloride, fluorouracil, and leucovorin calcium (IrMdG) in low topo-1 tumors
  4. Progression-free survival of patients with high topo-1 tumors treated with IrMdG with or without oxaliplatin
  5. Efficacy of IrMdG with vs without cetuximab in K-ras wildtype tumors
  6. Efficacy of IrMdG with vs without bevacizumab in K-ras mutant tumors

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Leeds Cancer Centre at St. James's University Hospital

    Leeds, England, United Kingdom

  • Belfast City Hospital Trust Incorporating Belvoir Park Hospital

    Belfast, Northern Ireland, United Kingdom

  • Velindre Cancer Center at Velindre Hospital

    Cardiff, Wales, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.